CiteFacts · FDA Drug Shortages · FDA source
Remifentanil Hydrochloride Injection
Status
FDA currently lists this ingredient in shortage.
This is nationwide FDA status, not local pharmacy inventory. CiteFacts does not provide medical, treatment, substitution, or dosing advice.
FDA package and manufacturer records
| Company | Presentation | FDA availability field | FDA update |
|---|---|---|---|
| Fresenius Kabi USA, LLC | Remifentanil Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-723-03) | Available | 08/04/2026 |
| Fresenius Kabi USA, LLC | Remifentanil Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-724-05) | Unavailable | 08/04/2026 |
| Fresenius Kabi USA, LLC | Remifentanil Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-725-10) | Available | 08/04/2026 |
| Hikma Pharmaceuticals USA, Inc. | Remifentanil Hydrochloride, Injection, 1 mg per vial (NDC 0143-9391-10) | Unavailable | 08/13/2026 |
| Hikma Pharmaceuticals USA, Inc. | Remifentanil Hydrochloride, Injection, 2 mg per vial (NDC 0143-9392-10) | Unavailable | 08/13/2026 |
| Hikma Pharmaceuticals USA, Inc. | Remifentanil Hydrochloride, Injection, 5 mg per vial (NDC 0143-9393-10) | Available | 08/13/2026 |
| Mylan Institutional, a Viatris Company | Ultiva, Injection, 1 mg/1 mL (NDC 72078-034-01) | Available | 08/20/2026 |
| Mylan Institutional, a Viatris Company | Ultiva, Injection, 2 mg (NDC 72078-035-02) | Available | 08/20/2026 |
| Mylan Institutional, a Viatris Company | Ultiva, Injection, 5 mg (NDC 72078-036-05) | Available | 08/20/2026 |
Source facts
Grouped generic ingredient: Remifentanil Hydrochloride Injection · 9 package records · Latest FDA row update: 08/20/2026
Therapeutic categories: Analgesia/Addiction
Dosage forms: Injection
Routes: INTRAVENOUS
Open FDA source data · JSON · Markdown
FDA is authoritative. Source retrieved 2026-08-22T15:54:11+00:00. Derived grouping is documented in this record's derivations.